THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS St Peter Port, Guernsey 9 January 2025 NB Private Equity Partners (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 12 June 2024 and the share buy-back agreement with Jefferies International Limited. Transaction on ...

Strategic Partnership and Expansion - Dékuple Group accelerates its European expansion by acquiring majority stakes in Selmore (Amsterdam) and DotControl (Rotterdam) [1] - The partnership aims to build a next-generation agency model in Europe, combining data, technology, and creativity to meet evolving market needs [4] - This move strengthens Dékuple's footprint in Europe and enhances its expertise portfolio to better serve international clients [1] Company Profiles - Selmore, founded in 2005, is a strategic and creative agency based in Amsterdam, known for its innovative "Guiding Ideas" and work with leading brands such as Škoda, Domino’s Pizza, and ASN Bank [2] - DotControl, also founded in 2005, is a leading digital engagement agency based in Rotterdam, specializing in strategic digital projects for clients like Disney, DPG Media, and Feyenoord football club [3] - Together, Selmore and DotControl generate annual net sales of approximately €7 million, with a gross margin exceeding €5 million [8] Strategic Goals and Synergies - The partnership aligns with Dékuple's European growth strategy, which combines organic initiatives and targeted acquisitions to diversify activities and expand offerings [5] - Dékuple leverages its multi-entrepreneur model to capitalize on synergies and complementary expertise while preserving the autonomy of Selmore and DotControl [5] - The integration aims to unlock new market opportunities, create value for clients, and shape the future of marketing and communications across Europe [8] Leadership and Vision - Bertrand Laurioz, Chairman and CEO of Dékuple Group, emphasizes the goal of strengthening the company's European footprint and enhancing expertise to meet transnational client needs [6] - Anja Froeling, CEO of Selmore, and Mark Landman, CEO of DotControl, highlight the added value of combining strategic, creative, and digital expertise to maximize brand visibility and effectiveness [7] Financial and Operational Impact - Selmore and DotControl will be consolidated into Dékuple's accounts as of January 1, 2025 [8] - Dékuple, founded in 1972, recorded net sales of €200 million in 2023 and employs over 1,000 people across Europe, North America, and China [8]

Key Announcement - VEON Ltd appoints Burak Ozer as Group Chief Financial Officer (Group CFO), effective 9 January 2025 [1] - Burak Ozer succeeds Joop Brakenhoff, who will continue as an Advisor to the Group CEO [1] Burak Ozer's Background - Burak Ozer brings over 27 years of international finance experience [2] - He started his career at Xerox, holding key financial positions in the USA and UK, and served as General Manager of Xerox Turkey [2] - Most recently, he was CFO in the global Digital Transformation, IT Solutions & Cybersecurity sector [2] Leadership Comments - VEON Group CEO Kaan Terzioglu welcomes Burak Ozer, citing his international experience and track record as invaluable for VEON's repositioning in frontier markets [3] - Terzioglu expresses gratitude to Joop Brakenhoff for his years of service and looks forward to his continued advisory role [3] - Burak Ozer expresses excitement to join VEON during a pivotal growth and innovation phase, aiming to drive growth and ensure strong financial governance [3] About VEON - VEON is a global digital operator serving nearly 160 million customers across six countries, representing over 7% of the world's population [4] - The company provides converged connectivity and digital services, transforming lives through technology-driven services in areas like connectivity, financial services, entertainment, education, and healthcare [4] - VEON is listed on NASDAQ [4]

Supervisory Board Changes - Jan van Nieuwenhuizen, Chairman of the Supervisory Board, will not seek a second term and will step down after the AGM on 17 April 2025 [1] - The Supervisory Board and Executive Board express regret over his decision and acknowledge his contributions to the company's strategy and sustainability efforts [1] - The Supervisory Board will consider appointing a new chairman from its members and begin recruiting a new Supervisory Board member [1] Company Overview - ForFarmers is a leading European company providing complete feed solutions for livestock farming, with a focus on sustainability and future-proof farming [2] - The company sold approximately 8.4 million tonnes of animal feed in 2023, generating a turnover of around €3 billion [2] - ForFarmers operates production facilities in the Netherlands, Germany, Poland, and the UK, and exports to various countries within and outside Europe [2] - The company employs around 2,600 people and is listed on Euronext Amsterdam [2] Strategic Focus - ForFarmers' mission is "For the Future of Farming," aiming to contribute to sustainable agriculture and robust long-term earnings [2] - The company emphasizes knowledge sharing, advice, support, and product innovation to help farmers achieve good returns and sustainable practices [2] - ForFarmers is committed to contributing to affordable and sustainable food production [2]

In 2024 Q4, 1.9 million passengers and 3.4 million tons of cargo passed through the harbors of Tallinna Sadam. Compared to the same period of previous year, the number of passengers increased by 4.8% supported by Finnish lines and the cargo volume increased by 11.7%, most of it in dry bulk and containers. The number of vessel calls increased by 4.8% reaching 1857 calls. The number of passengers travelling between the Estonian mainland and the main islands increased by 4.3% and the number of vehicles increas ...

TGS Q4 2024 Operational Update OSLO, Norway (9 January 2025) – TGS, a leading global provider of energy data and intelligence routinely publishes a quarterly operational update six working days after quarter-end. The table below shows TGS’s normalized Ocean Bottom Node (OBN) crew count: 202220232024Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2<td style="width:45px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ...

Study Results - The IRAKLIA phase 3 study demonstrated that the subcutaneous (SC) formulation of Sarclisa, administered via an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone (Pd), met its co-primary endpoints of non-inferior objective response rate (ORR) and observed concentration before dosing (C trough) at steady state compared to intravenous (IV) Sarclisa in patients with relapsed or refractory multiple myeloma (R/R MM) [1] - Key secondary endpoints, including very good partial response (VGPR), incidence rate of infusion reactions, and C trough at cycle 2, were also achieved [1] - The study enrolled 531 patients across 252 global sites, with patients randomized to receive either SC or IV Sarclisa in combination with Pd for 28-day cycles until disease progression or other discontinuation criteria were met [4] Subcutaneous Formulation and OBDS - The SC formulation of Sarclisa, delivered via the enFuse OBDS, represents a potential new administration option for patients, offering comparable efficacy and safety to the IV formulation [2] - The enFuse OBDS, developed by Enable Injections, is designed to administer high-volume medicines subcutaneously through an automated drug delivery technology, featuring a hidden and retractable needle that is thinner than commonly used SC injection needles [2][7] - The IRAKLIA study is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS, aiming to improve the patient experience and reduce time spent in healthcare facilities [5] Regulatory and Clinical Development - Regulatory submissions for the SC formulation of Sarclisa are planned in the US and EU during the first half of 2025 [3] - Additional studies evaluating Sarclisa SC formulations across different combinations and lines of therapy are ongoing, with the safety and efficacy of the SC formulation and enFuse device yet to be evaluated by regulatory authorities outside of their approved indications [3][8] About Sarclisa - Sarclisa (isatuximab) is a CD38 monoclonal antibody that targets MM cells through multiple mechanisms of action, including apoptosis and immunomodulatory activity [8] - Currently approved in more than 50 countries, Sarclisa is indicated for the treatment of R/R MM in combination with Pd or carfilzomib and dexamethasone, and as a front-line treatment option for newly diagnosed MM in combination with VRd [8] Sanofi's Strategic Focus - Sanofi is committed to advancing oncology innovation, with a focus on difficult-to-treat cancers such as multiple myeloma, acute myeloid leukemia, and certain lymphomas, as well as gastrointestinal and lung cancers [9] - The company continues to advance Sarclisa as part of a patient-centric clinical development program, with several phase 2 and phase 3 studies across the MM treatment continuum [8][9]

London Takes The Top Spot – Plus, U.S. Favorite Places for Food, Culture, Solo Travel and MoreNEEDHAM, Mass., Jan. 9, 2025 /PRNewswire/ -- Tripadvisor®, the world's largest travel guidance platform, today announced its first Travelers' Choice® Awards category for 2025: Best of the Best Destinations. London, UK Each year, Tripadvisor pores over millions of reviews shared by a global community of travelers to uncover the most trusted recommendations, helping future explorers create unforgettable memories ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Chipotle Mexican Grill, Inc. (NYSE: CMG) between February 8, 2024 and October 29, 2024, both dates inclusive (the “Class Period”) and those who purchased Chipotle call options or sold put options during the Class Period, of the important January 10, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Chipotle sec ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zeta Global Holdings Corp. (NYSE: ZETA) between February 27, 2024 and November 13, 2024, both dates inclusive (the “Class Period”), of the important January 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zeta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...